Get the Stockscreener App
1.34
1.52%
0.02
Rein Therapeutics Inc stock is traded at $1.34, with a volume of 41,998.
It is up +1.52% in the last 24 hours and up +12.61% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.32
Open:
$1.33
24h Volume:
41,998
Relative Volume:
0.34
Market Cap:
$31.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.94%
1M Performance:
+12.61%
6M Performance:
-19.28%
1Y Performance:
+0.00%
1-Day Range:
$1.30
$1.34
1-Week Range:
$1.24
$1.4399
52-Week Range:
$1.04
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.34 | 31.71M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Why Rein Therapeutics Inc. stock attracts high net worth investorsDollar Strength & Consistent Growth Equity Picks - newser.com
What does recent volatility data suggest for Rein Therapeutics Inc.CEO Change & Safe Capital Preservation Plans - newser.com
Will Rein Therapeutics Inc. stock pay special dividends2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Why DCM Nouvelle Limited Stock Might Outshine Tech Rivals in YEARMarket Breadth Indicators & Predict Price Movements With AI Precision - earlytimes.in
Real time scanner hits for Rein Therapeutics Inc. explainedDay Trade & Real-Time Price Movement Reports - newser.com
Rein Therapeutics receives EMA approval for IPF drug trial in Europe - Investing.com Canada
Rein Therapeutics Receives EMA Approval for Phase 2 IPF Trial - TradingView
Rein Therapeutics receives European regulatory approval to initiate phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis - MarketScreener
Rein Therapeutics Receives European Regulatory Approval to - GlobeNewswire
Detecting support and resistance levels for Rein Therapeutics Inc.2025 Market Outlook & High Yield Stock Recommendations - newser.com
Has Rein Therapeutics Inc. found a price floorMarket Risk Report & Reliable Entry Point Trade Alerts - newser.com
Sector ETF performance correlation with Rein Therapeutics Inc.2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
Titan Acquisition Corp Debt Equity Composite Units Stock Analysis and ForecastMarket Entry Points & Exceptional Growth Portfolio - earlytimes.in
Can trapped investors hope for a rebound in Rein Therapeutics Inc.Earnings Miss & Real-Time Chart Breakout Alerts - newser.com
What drives Rein Therapeutics Inc stock priceLong-Term Investment Plans & Exceptional Profit Trading - earlytimes.in
Can Sunteck Realty Limited Stock Sustain Its Uptrend in a Bear Market - earlytimes.in
Rein Therapeutics Inc. stock trend outlook and recovery pathGold Moves & AI Enhanced Trading Signals - newser.com
What Valuation Gaps Could Correct in The Ruby Mills Limited Stock Price - earlytimes.in
Momentum divergence signals in Rein Therapeutics Inc. chartMarket Risk Analysis & Low Risk High Reward Trade Ideas - newser.com
Voss Capital, LP's Strategic Acquisition in Rein Therapeutics Inc - GuruFocus
What analysts say about Ease2pay NV DOC2 stockStock Watchlist Updates & Low Cost Market Strategies - earlytimes.in
Rein Therapeutics (RNTX) Price Target Increased by 42.86% to 10.20 - Nasdaq
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):